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INTRODUCTION  
Nonalcoholic fatty liver disease (NAFLD) is 
one of the most common causes of chronic liver 
injury worldwide. NAFLD causes a wide spectrum 
of liver diseases that range from simple steatosis 
to nonalcoholic steatohepatitis (NASH), advanced 
¿EURVLV FLUUKRVLV DQG KHSDWRFHOOXODU FDUFLQRPD
2EHVLW\ H[FHVV LQWDNH RI FDORULHV DQG LQVXOLQ
resistance which results in an increased release of 
free fatty acids from adipocytes and increased rates 
of fatty acid synthesis in the liver are considered to be 
common causes of NAFLD(2,3). There are two step 
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Background: 
Ezetimibe inhibits the resorption of dietary and biliary cholesterol in the small intestine and decreases insulin resis-
tance in patients with nonalcoholic fatty liver disease (NAFLD). Acarbose has been used in type 2 diabetes mellitus 
and metabolic syndrome. This study aims to compare the therapeutic effects of ezetimibe and acarbosein decreasing 
liver transaminase levels in patients with NAFLD.
Materials and Methods:  
This was a single center, double-blind, parallel-group study conducted at Bu-Ali Sina Hospital, Qazvin, Iran. In this 
trial, we enrolled, by simple randomization,  a total of 62 patients diagnosed with NASH. There were 29 patients 
treated with ezetimibe and 33 who were treated with acarbose over a ten-week period.
Results:    
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cholesterol, high-sensitivity C-reactive protein (hsCRP), and serum insulin levels and the insulin resistance ho-
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Conclusion:       
Both ezetimibe and acarbose improved metabolic and biochemical abnormalities in patients with NASH, however 
these effects were more prominent with ezetimibe.
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LQ 1$)/'  OLSLG DFFXPXODWLRQ DQG VWHDWRVLV ¿UVW
VWHSDQGQHFURVLVLQÀDPPDWLRQDQG¿EURVLVVHFRQG
step)(4). To date, no single therapy has been approved 
to treat NAFLD, however initial management must 
IRFXV RQ OLIHVW\OH PRGL¿FDWLRQ DQG WKH UHYHUVDO RI
conditions associated with NAFLD.
Ezetimibe is a novel, potent cholesterol-decreasing 
drug that selectively binds to the cholesterol transporter 
Niemann-Pick C1-Like 1 (NPC1L1) and inhibits the 
resorption of dietary and biliary cholesterol in the 
VPDOO LQWHVWLQH DQG OLYHU(]HWLPLEH VLJQL¿FDQWO\
decreases plasma alanine aminotransferase 
DFWLYLW\ WXPRU QHFURVLV IDFWRU 71)Į DQG LQVXOLQ
resistance(6,7) and has a suppressive effect on fatty 
liver(6,8-10). In addition to these roles, recent studies 
suggest that ezetimibe affects insulin resistance(11). 
Nevertheless; the mechanism whereby ezetimibe 
achieves these favorable effects on insulin sensitivity 
are not well understood.
$FDUERVH DQ ĮJOXFRVLGDVH LQKLELWRU LV DQRWKHU
drug found to be useful in NAFLD and type 2 
diabetes(12,13). A strong correlation between 
diabetes and NAFLD has been shown in previous 
studies(14,15).Acarbose improves liver function in 
NAFLD in patients with metabolic syndrome(16).To 
the best of our knowledge, no randomized clinical trial 
has evaluated ezetimibe and acarbosemonotherapy in 
humans diagnosed with NAFLD. The aim of this study 
was to compare the therapeutic effects of ezetimibe 
and acarbose in patients with NAFLD.
MATERIALS AND METHODS  
From January 2011 to December 2012, we 
assessed 62 patients with NAFLD for eligibility to 
enter the study. This was a single center, double-
blind, parallel-group study conducted in Bu-Ali Sina 
Hospital, Qazvin, Iran. Patients were randomized via 
simple randomization.
NAFLD was diagnosed according to the presence 
RIZLGHVSUHDGIDWLQWKHOLYHUDVLGHQWL¿HGE\DEULJKW
liver pattern with liver-kidney contrast and vascular 
EOXUULQJE\HFKRWH[WXUHLQXOWUDVRQRJUDSK\LQDGGLWLRQ
to elevations in alanine aminotransferase (ALT >40 
mg/dl in men and ALT >31 mg/dl in women). 
([FOXVLRQ FULWHULD ZHUH GLDEHWHV PHOOLWXV RU
previous use of anti-diabetic medications that 
included insulin-sensitizing agents such as metformin 
DQGSLRJOLWD]RQHDOFRKRO LQWDNHH[FHHGLQJJGD\
and those who reported any signs, symptoms, and/or 
history of known liver disease (viral, metabolic, or 
autoimmune) or drug-induced liver disease, previous 
anti-hyperlipidemic treatment and patients with 
heart failure or renal failure. The study protocol was 
approved by the Ethical Committee of Bu-Ali Sina 
Hospital and informed consent was obtained from all 
subjects prior to enrollment in the study.
All patients were assessed by abdominal 
ultrasonography and biochemical tests before 
WUHDWPHQW1HLWKHU GLHWDU\ QRU H[HUFLVH WKHUDS\ZDV
prescribed and their lifestyles remained unchanged.
Patients were randomly assigned to one of two groups 
according to the method of treatment: ezetimibe 
(n=29) and acarbose (n=33). Patients in group 1 
received ezetimibe (10 mg/day) while subjects in 
group 2 were treated with acarbose (50 mg, twice 
daily). Demographic characteristics of patients 
in each group are shown in Table 1. All patients 
returned for follow up visits at our center ten weeks 
after beginning treatment. At the follow up visit, we 
REWDLQHGERG\ZHLJKWERG\PDVVLQGH[%0,VHUXP
ALT, AST, triglycerides, total cholesterol, low-density 
lipoprotein (LDL) cholesterol, fasting blood sugar 
(FBS), high-sensitivity C-reactive protein (hsCRP), 
and serum insulin levels and insulin resistance 
KRPHRVWDVLV PRGHO DVVHVVPHQW +20$,5 LQGH[
which were compared with baseline levels in both 
groups.
Statistical analyses were performed using SPSS 
software (Statistical Package for the Social Sciences, 
V. 16.0; SPSS Inc, Chicago, IL, USA). Data were 
summarized by frequencies and percentages for 
categorical variables and means ± SD for continuous 
variables. Comparison of pre- and post treatment of 
ezetimibe and acarbose groups were carried out using 
repeated measures analysis. A p value less than 0.05 
ZDVFRQVLGHUHGVWDWLVWLFDOO\VLJQL¿FDQW
RESULTS  
Patients' ages were 40.6±2.3 years for the 
ezetimibe group and 40.6±10.8 years for the acarbose 
group (p=1). There were 16 (55.2%) patients in the 
ezetimibe group and 19 (61.3%) in the acarbose 
group who were male (p=0.8). We observed  no 
VLJQL¿FDQW GLIIHUHQFHV LQ EDVHOLQH FKDUDFWHULVWLFV RI
patients in both groups (Table 1). Ezetimibe treatment 
VLJQL¿FDQWO\ UHGXFHG$/7p<0.001), AST(p<0.001), 
triglycerides(p<0.001), total cholesterol(p<0.001), 
LDL cholesterol(p<0.001), hsCRP(p<0.001) and 
serum insulin levels(p<0.001). There was a reduction 
LQWKH+20$,5LQGH[p<0.001) as well (Table 2).  
Similar results were obtained with acarbose 
treatment. Body weight(p<0.001), BMI(p<0.001), 
Ezetimibe & Acarbose in Fatty liver
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ALT (p<0.001), AST (p<0.001), triglycerides 
(p<0.001), total cholesterol (p<0.001), LDL 
cholesterol (p<0.001), and serum insulin levels 
(p LQ DGGLWLRQ WR WKH +20$,5 LQGH[
(pGHFUHDVHGVLJQL¿FDQWO\LQWKLVJURXS7DEOH
2). 
In a comparison between ezetimibe and acarbose 
treatment, we found that ezetimibe treatment had 
VLJQL¿FDQWO\ KLJKHU GHFUHDVHG $/7 p=0.05), AST 
(p=0.01), total cholesterol (p=0.01), HDL cholesterol 
(p=0.03) and LDL cholesterol (p=0.03) levels. 
However acarbose treatment decreased body weight 
DW D VLJQL¿FDQWO\KLJKHU UDWH FRPSDUHG WR H]HWLPLEH
(p=0.04). No substantial differences were found in 
Hajiaghamohammadi et al.
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Table 1: Demographic and biochemical parameters.
Ezetimibe (n=29) Acarbose (n=33) p-value
Male (%) 16 (55.2) 19 (61.3) 0.8
Age (years) 40.6±2.3 40.6±10.8 1
Body weight (kg) 80.4±10.6 80.8 ±12.5 1
BMI (kg/m2) 30.5±11.9 30.1±9.4 1
AST 54.7±22.5 50.8±16.6 0.3
ALT 94.6±56.0 87.5±27.8 0.4
Triglycerides 178.2±73.3 189.7±89.1 0.8
Total cholesterol 214.6±47 206.4±40.3 0.8
HDL cholesterol 42.4±7.0 39.40±8.2 0.6
LDL cholesterol 136.5±47.6 129.1±31.2 0.8
Fasting blood sugar (FBS) 98.6±12.7 94.1±14.1 0.4
Serum insulin 14.6±6.8 14.8±7.6 1
hsCRP* 2.3±2.1 2.1±2.5 1
HOMA  index 3.6±1.8 3.4±1.7 0.8
*hsCRP: High-sensitivity C-reactive protein
Table 2: Patients' clinical characteristics before and after treatment.
Variables











Body weight (kg) 80.4±10.6 79.5±11.5 0.2 80.8 ±12.5 77.4±11.7 <0.001 0.04
BMI (kg/m2) 30.5±11.9 30.1±10.9 0.2 30.1±9.4 28.8±8.5 <0.001 0.11
AST 54.7±22.5 33.2±13 <0.001 50.8±16.6 40.7±12.4 <0.001 0.01
ALT 94.6±56.0 52.8±28.4 <0.001 87.5±27.8 61.5±23.8 <0.001 0.05
Triglycerides 178.2±73.3 146.1±69.2 <0.001 189.7±89.1 161.9±68.1 <0.001 0.7
Total cholesterol 214.6±47 178.1±37.2 <0.001 206.4±40.3 189.5±32.1 <0.001 0.01
HDL cholesterol 42.4±7.0 41.0±5.7 0.2 39.40±8.2 40.6± 7.9 0.07 0.03
LDL cholesterol 136.5±47.6 107.9±35.4 <0.001 129.1±31.2 116.4±26 <0.001 0.03
Fasting blood 
sugar (FBS) 98.6±12.7 97.1±14.1 0.4 94.1±14.1 93.6±12.3 0.7 0.7
Serum insulin 14.6±6.8 11.12±5.7 <0.001 14.8±7.6 12.5±17.0 <0.001 0.2
hsCRP* 2.3±2.1 1.6±1.2 <0.001 2.1±2.5 1.6±1.2 0.11 0.5
HOMA index 3.6±1.8 2.7±1.7 <0.001 3.4±1.7 2.9±1.8 <0.001 0.12
  
*hsCRP: High-sensitivy C-reactive protein.
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BMI (p=0.11), FBS (p=0.7), triglycerides (p=0.7), 
hsCRP (p=0.5) and serum insulin (p=0.2) levels and 
+20$,5 LQGH[ p=0.12) between the two groups 
(Table 2).
DISCUSSION  
We compared the effects of ezetimibe, an intestinal 
cholesterol transporter inhibitor, to acarbose, an 
alfa-glucosidase inhibitor, as treatment for NAFLD. 
+RZHYHU OLIHVW\OH PRGL¿FDWLRQ DQG FRJQLWLYH
behavior therapy aimed at weight reduction with 
GHFUHDVHG FDORULH LQWDNH DQG H[HUFLVH KDYH EHHQ
considered as the main therapy for this metabolic 
syndrome(17).  
8VH RI LQVXOLQ VHQVLWL]HUV DQWLR[LGDQWV DQWL
obesity, herbal and lipid lowering medications can be 
effective(18,19).  
Previous studies have researched the therapeutic 
effects of ezetimibe in NAFLD patients and animal 
models. In a study by Nazaky, ezetimibe therapy led 
to improvement in lipid metabolic disorders(20). 
Tamaki studied the effect of ezetimibe on metabolic 
syndrome. He observed that ezetimibe reduced 
serum LDL, CRP, AST, and ALT levels and increased 
HDL levels(21).De Bario who studied the effects 
of ezetimibe on NAFLD observed that inhibition 
RI WKH13&/ UHFHSWRU DQG LQWHVWLQDO VWHURO LQÀX[
transporter diminished serum cholesterol levels and 
regulated fatty acid metabolism in the fatty liver(22).  
Results of a study by Fillipatose on fatty liver 
VKRZHG WKH HI¿FDF\ RI H]HWLPLEH LQ GHFUHDVLQJ
ALT levels(23). According to Musso in a study of 
treatment of fatty liver,  althoughezetimibe decreased 
plasma lipid levels and improved liver histology, it 
was ineffective on glucose metabolism and HbA1C 
OHYHOV )LQDOO\ <RVKLGD GHVFULEHG WKH HI¿FDF\
of ezetimibe on dyslipidemia and decreased insulin 
resistance(25).
This study researched the effects of ezetimibe on 
the fatty liver. As with previous studies, the results 
noted decreased levels of ALT, AST, triglycerides, 
total cholesterol, LDL, FBS, serum insulin level and 
&537KH+RPDLQGH[ZKLFKLVFRUUHODWHGZLWKLQVXOLQ
resistance improved with ezetimibe. HDL levels 
VLJQL¿FDQWO\LQFUHDVHGZLWKWKLVWUHDWPHQW7DEOH
Improvement of fat metabolism with ezetimibe due 
WRLQKLELWLRQRIJXWFKROHVWHURODEVRUSWLRQLVH[SHFWHG
but the additional effects on glucose metabolism 
and improvement in insulin resistance should be 
H[SODLQHG
There are some studies about the effects of 
acarbose on metabolic syndrome. Nazaki, in his 
VWXG\SUHVFULEHGDFDUERVHIRUHI¿FDF\RQUHJXODWLRQ
RI OLSLG SUR¿OHV LQ PHWDEROLF V\QGURPH ZKLFK
would be synergistic with ezetimibetherapy(20). In 
a study by Yamagish, acarbose therapy decreased 
triglyceride levels and insulin resistance(26).Lieber 
observed decreased serum levels of a marker of 
LQÀDPPDWLRQ/HWRUH[SODLQHGWKDWDFDUERVHDVDQ
alpha glucosidase inhibitor decreased not only insulin 
resistance but also plasma cholesterol levels(28).
7KH UHVXOWV RI RXU VWXG\ DERXW WKH HI¿FDF\ RI
acarbose in fatty liver treatment showed that it 
decreased ALT, triglycerides, cholesterol and LDL 
levels. We observed increased HDL levels and 
improved insulin resistance. However when compared 
to ezetimibe, acarbose decreased plasma sugar levels 
more potently and was less effective in decreasing 
ALT and AST levels  (Table 2). We observed no 
serious side effects from either medication during the 
course of the treatment.
Future research on these pathways and the use 
of combined therapy in treatment of NAFLD 
can be useful and increase knowledge about its 
pathophysiology.  
Both ezetimibe and acarbose improved metabolic 
and biochemical abnormalities in patients with 
NAFLD. Although the decrease in body weight 
ZDV VLJQL¿FDQW IRU DFDUERVH WUHDWPHQW H]HWLPLEH
treatment decreased NAFLD abnormality to a 
KLJKHU H[WHQW WKDQ DFDUERVH (]HWLPLEH DSSHDUHG WR
be a more potent agent in NAFLD treatment than 
acarbose. However due to differences in mechanisms 
of ezetimibe and acarbose, further studies of longer 
GXUDWLRQDUHQHFHVVDU\LQRUGHUWRFODULI\WKHHI¿FDF\
of combination therapy with these two drugs.
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